Drug-induced rhabdomyolysis (DIR) is an idiosyncratic and fatal adverse drug reaction (ADR) characterized in severe muscle injuries accompanied by multiple-organ failure. Limited knowledge regarding the pathophysiology of rhabdomyolysis is the main obstacle to developing early biomarkers and prevention strategies. Given the lack of a centralized data resource to curate, organize, and standardize widespread DIR information, here we present a Drug-Induced Rhabdomyolysis Atlas (DIRA) that provides DIR-related information, including: a classification scheme for DIR based on drug labeling information; postmarketing surveillance data of DIR; and DIR drug property information. To elucidate the utility of DIRA, we used precision dosing, concomitant use of DIR drugs, and predictive modeling development to exemplify strategies for idiosyncratic ADR (IADR) management.

中文翻译：

---

用于特异药物不良反应管理的药物诱导的横纹肌溶解图集（DIRA）。

药物诱发的横纹肌溶解症（DIR）是一种特发性和致命的药物不良反应（ADR），其特征是严重的肌肉损伤并伴有多器官衰竭。有关横纹肌溶解症的病理生理学的有限​​知识是发展早期生物标记物和预防策略的主要障碍。鉴于缺乏集中的数据资源来管理，组织和标准化广泛的DIR信息，在这里，我们介绍一种药物诱导的横纹肌溶解图集（DIRA），该图谱提供与DIR相关的信息，包括：基于药物标签信息的DIR分类方案; DIR的上市后监视数据；和DIR药物特性信息。为了阐明DIRA的效用，我们使用了精确剂量，同时使用了DIR药物，